Compare Salesforce Inc (CRM) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Enveric Biosciences Inc — how do they compare? Salesforce Inc trades at $227.46 (market cap $184.81B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Salesforce Inc is far larger — about 27624.8× Enveric Biosciences Inc's market cap, and Salesforce Inc pays a 0.78% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Enveric Biosciences Inc for 14 Days on average.
| CRM | ENVB | |
|---|---|---|
Market Cap | $184.81B | $6.69M |
Volume | 5,173,995 | 41,141 |
Sector | Technology | Health |
52-Week High | $266.23 | $10.80 |
52-Week Low | $150.12 | $1.27 |
Typical Hold Time | 89 Days | 14 Days |
Enterprise Value | $215.15B | -$1.60M |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $227.80, up 1.25% with a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $5.90 versus $3.27 expected. Revenue grew to $37.90B in 2025 with impressive 77.28% gross margins and 21.99% net income margin. Analyst consensus remains strongly bullish with 76.5% buy ratings and $271.91 price target, representing 19% upside potential.
The stock presents a compelling value opportunity with reasonable P/E of 20.56 and strong profitability metrics, though technical indicators signal near-term weakness. Key risks include AI-driven software sector volatility and macroeconomic headwinds affecting enterprise spending. Current levels offer attractive entry for long-term investors given the company's dominant market position and consistent execution.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
